Literature DB >> 22162176

The limited screening value of insulin-like growth factor-I as a marker for alterations in body composition in very long-term adult survivors of childhood cancer.

Karin Blijdorp1, Marry van den Heuvel-Eibrink, Rob Pieters, Annemieke Boot, Johanna Sluimer, Aart-Jan van der Lelij, Sebastian Neggers.   

Abstract

BACKGROUND: The clinical relevance of low IGF-I levels, caused by cranial radiotherapy, in adult childhood cancer survivors has not been studied extensively. We evaluated whether IGF-I is a useful marker for altered body composition and growth hormone deficiency (GHD) in this group. PROCEDURE: We analyzed retrospective data from 610 adult childhood cancer survivors, retrieved from the late effects clinic. Median age at diagnosis was 6 years (interquartile range 3-11) and follow-up time was 18 years (13-24). We assessed IGF-I standard deviation scores (SDS), anthropometrical measures, growth hormone stimulation tests in patients with clinical signs of GHD, and measures of body composition (assessed by dual X-ray absorptiometry, Lunar Prodigy).
RESULTS: In 58 cranially irradiated acute leukemia survivors (25 Gy (24-25)) and 56 locally irradiated brain tumor survivors (42 Gy (35-54)) we found significantly lower IGF-I SDS (P < 0.001), lower height SDS (P < 0.001), higher body mass index (P = 0.01), higher waist-hip ratio (WHR; P = 0.001), higher total fat percentage SDS (P < 0.001), and lower lean body mass SDS (P < 0.001), as compared to 452 not cranially irradiated survivors. IGF-I showed a weak inverse correlation with BMI (r = -0.12, P = 0.04), WHR (r = -0.15, P = 0.01), total fat percentage (r = - 0.14, P = 0.02), and a positive correlation with lean body mass (r = 0.15, P = 0.01). In patients with low IGF-I levels, IGF-I did not significantly differ between subjects with and without GHD as determined by GH-stimulation testing (P = 0.39).
CONCLUSION: This study shows that IGF-I has limited value as a marker for alterations in body composition in adult childhood cancer survivors.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22162176     DOI: 10.1002/pbc.24015

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk factor profile in childhood cancer survivors.

Authors:  Anna Petryk; K Scott Baker; Brigitte Frohnert; Antoinette Moran; Lisa Chow; Alan R Sinaiko; Lyn M Steffen; Joanna L Perkins; Lei Zhang; James S Hodges; Julia Steinberger
Journal:  Pediatr Blood Cancer       Date:  2012-09-21       Impact factor: 3.167

Review 2.  Endocrinopathies in survivors of childhood neoplasia.

Authors:  Nicole Barnes; Wassim Chemaitilly
Journal:  Front Pediatr       Date:  2014-09-23       Impact factor: 3.418

Review 3.  Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors.

Authors:  Cecilia Follin; Eva Marie Erfurth
Journal:  Curr Treat Options Oncol       Date:  2016-09

4.  Expert Opinion on the Management of Growth Hormone Deficiency in Brain Tumor Survivors: Results From an Italian Survey.

Authors:  Natascia Di Iorgi; Giovanni Morana; Marco Cappa; Ludovico D'Incerti; Maria Luisa Garrè; Armando Grossi; Lorenzo Iughetti; Patrizia Matarazzo; Maria Parpagnoli; Gabriella Pozzobon; Mariacarolina Salerno; Iacopo Sardi; Malgorzata Gabriela Wasniewska; Stefano Zucchini; Andrea Rossi; Mohamad Maghnie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

5.  Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.

Authors:  Marjolein van Waas; Sebastian J C M M Neggers; Hein Raat; Caroline M van Rij; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.